Skip to main content

Informax Licenses Genomax to Cellular Genomics

NEW YORK, May 14 – Bioinformatics company Informax said Monday it signed a deal in the first quarter to license its Genomax software to Cellular Genomics.

An Informax spokeswoman said the deal was recorded in the company’s first quarter earnings although the official announcement was held up due to internal delays.

“These products will form a key element of CGI's bioinformatics infrastructure, allowing us to rapidly meet our needs of high throughput sequence analysis for our protein-protein interaction screens, as well as gene expression analysis for our target validation work,” Andy Whitney, Cellular Genomics’ director of bioinformatics, said in a statement.

Terms of the deal were not disclosed.

Genomax is an enterprise system that supports high-throughput research. Genomax can handle genomic and proteomic data, including sequence information, gene expression data, and protein structure.

To date, Informax of Bethesda, Md., has licensed Genomax to over 30 pharmaceutical, biotechnology, and academic customers.

Cellular Genomics of Branford, Conn., identifies and validates novel drug targets and plans to develop its own pharmaceutical products.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.